Overview
LYEL market data
Price History
LYEL price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$16.06 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.04 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -794,858.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $9.28 – $45.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $351.2M · P/B 2.63 · P/S 11,327.70.
Company News
8-K filing — Lyell Immunopharma, Inc. (LYEL)SEC EDGAR · Aug 6, 2026, 8:14 PM
Lyell Immunopharma shares are trading higher after Stifel initiated coverage on the stock with a Buy rating and announced a $36 price target.Benzinga · Aug 6, 2026, 3:07 PM
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For ThursdayBenzinga · Aug 6, 2026, 2:12 PM
Stifel Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $36Benzinga · Aug 6, 2026, 10:08 AM
B. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44Benzinga · Jul 22, 2026, 10:42 AM
Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price TargetBenzinga · Jun 15, 2026, 2:10 PM
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 CongressGlobenewswire Inc · Jun 12, 2026, 5:15 PM
Lyell Immunopharma Announces Data From Its Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-cell Lymphoma Shows Manufacturing Success Rate Of 97%Benzinga · Jun 12, 2026, 4:55 PM
Lyell Immunopharma Issues Colorectal Cancer Drug Safety UpdateBenzinga · Jun 8, 2026, 2:25 PM
Lyell Immunopharma To Present Data From Its Current Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-Cell Lymphoma At European Hematology Association 2026 CongressBenzinga · Jun 4, 2026, 8:15 PM